Results 51 to 60 of about 51,116 (225)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Aliskiren, enalapril, or aliskiren and enalapril in heart failure [PDF]

, 2016
BACKGROUND Among patients with chronic heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown.
], Akshay S. Desai, Barry M. Massie, Claudio Borghi, for the ATMOSPHERE Committees Investigators [, Georgia Tarnesby, Henry Krum, John J.V. McMurray, Kenneth Dickstein, Lars V. Køber, M. Atif Ali, Nicola Greenlaw, Qing Shao, Scott D. Solomon, William T. Abraham, Yanntong Chiang   +15 more
core   +5 more sources

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial

European Journal of Heart Failure, 2022
We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n = 731) or post‐randomization drop‐in use (n = 425), to evaluate the relationship between the efficacy and safety of combination therapy with ...
M. Senni, W. Alemayehu, D. Sim, F. Edelmann, J. Butler, J. Ezekowitz, A. Hernandez, Carolyn S. P. Lam, C. O'connor, B. Pieske, P. Ponikowski, L. Roessig, A. Voors, C. Westerhout, C. McMullan, P. Armstrong   +15 more
semanticscholar   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial [PDF]

, 2017
Background: Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure.
Braunwald, Eugene, Cirino, Allison L., Colan, Steven D., Day, Sharlene M., Desai, Akshay S., Ho, Carolyn Y., Lipshultz, Steven E., MacRae, Calum A., McMurray, John J.V., Orav, E. John, Shi, Ling, Solomon, Scott D.   +11 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study [PDF]

, 2015
Objectives: While bidirectional relationships exist between body weight and physical activity, direction of causality remains uncertain and previous studies have been limited by self-reported activity or weight and small sample size.
Califf, Robert M., Davies, Melanie J., Gill, Jason M. R., Haffner, Steven M., Holman, Rury R., Kraus, William E., McMurray, John J., Preiss, David, Thomas, Laine E., Wojdyla, Daniel M., Yates, Thomas   +10 more
core   +2 more sources

Sacubitril/valsartan in the treatment of systemic right ventricular failure

Heart, 2021
Objective Pharmacological options for patients with a failing systemic right ventricle (RV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA (ccTGA) are not well defined.
T. Zandstra, M. Nederend, M. Jongbloed, P. Kiès, H. Vliegen, B. Bouma, L. Tops, M. Schalij, A. Egorova   +8 more
semanticscholar   +1 more source

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial

European Journal of Heart Failure, 2022
The win ratio can incorporate different types of outcomes and enhance statistical power, making it a useful method for analysing composite outcomes in cardiovascular trials. The application of this approach to the PARADISE‐MI trial provides an additional
O. Berwanger, M. Pfeffer, B. Claggett, K. Jering, A. Maggioni, P. Steg, R. Mehran, E. Lewis, Yinong Zhou, P. Meer, C. D. De Pasquale, B. Merkely, G. Filippatos, J. McMurray, C. Granger, S. Solomon, E. Braunwald   +16 more
semanticscholar   +1 more source